New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Hematology

Clinical discussions on blood disorders, coagulation, transfusion medicine, and hematologic malignancies.

Recent Discussions

Have you changed your practice in treating CRAO with IV thrombolysis?

5
5 Answers

Mednet MemberInvited Expert
Neurology · University of Virginia School of Medicine

The recent THEIA trial had a limited sample size to draw conclusions, even though there was a non-significant trend of improved visual acuity initially in the thrombolysis group. Even the TenCRAOS trial had a small sample size with recruitment challenges, where subtle small differences cannot be acc...

In a patient who has been receiving 1L Ibrutinib for TP53+ CLL for years with complete hematologic response but detectable MRD, is there any role to switch to the novel BTKi agents given better PFS?

4 Answers

Mednet Member
Medical Oncology · University of Kansas Cancer Center

There are a couple of features to this question that need comment. First, the goal of therapy with a single-agent BTKi, regardless of ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib, is NOT to achieve undetectable MRD. Very few patients will achieve this milestone due to the drug's MOA. BTK...

Would you consider using transdermal estrogen in a patient with “high risk” APLS patient on warfarin?

1
3 Answers

Mednet MemberInvited Expert
Hematology · Penn Medicine, University of Pennsylvania Health System

Given her clinical diagnosis of high-risk APS, I would first trial nonhormonal therapies or progesterone-only therapies for management of her post-menopausal symptoms. Current ACR guidance recommends against hormone replacement therapy in patients with APS on anticoagulation (Sammaritano et al., PMI...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

What approaches can we take to initiate therapy and improve survival rates in patients with HLH?

3
2 Answers

Mednet MemberInvited Expert
Infectious Disease · UT Southwestern School of Medicine

At our institution, we have comprised a multidisciplinary team to help treat these patients. The team or "HLH task force" as we like to call ourselves is comprised of a clinical immunologist, rheumatologist, dermatologist, critical care physician, hepatologist, BMT attending/hematologist, infectious...

How do you approach DOAC dose reduction for secondary prophylaxis of VTE in cancer-associated thrombosis?

1
2 Answers

Mednet MemberInvited Expert
Hematology · Mayo Clinic

Data from the API-CAT trial (Mahé et al., PMID 40162636) show that de-escalation of apixaban after 6 months was non-inferior compared to the standard dose with respect to recurrent VTE. Although there was no difference in major bleeding, the lower dose of apixaban was superior from the clinically re...

What dosing interval and doses do you use in practice when considering belantamab in elderly patients with relapsed myeloma?

1 Answers

Mednet MemberInvited Expert
Medical Oncology · Harvard Medical School

I generally use it every 8-12 weeks at 1.9 mg/m2. I start every 3 weeks and very quickly switch to every 8-12 weeks.

How to approach reversal of TNK in hemorrhagic conversion of ischemic stroke?

1
2 Answers

Mednet MemberInvited Expert
Neurology · University of Calgary

There is no specific "reversal agent" for tenecteplase. Once administered, the thrombolytic effect will persist until the drug is fully metabolized and any residual plasmin has been cleared by alpha-2-antiplasmin. So, perhaps the first question is what can you do if there is an acute bleeding event ...

How would you determine the safety of anticoagulation in patients with evidence of cerebral microhemorrhages who present with acute stroke secondary to cardioembolism?

4 Answers

Mednet MemberInvited Expert
Neurology · Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

There are observational data that suggest the relative safety of anticoagulation in patients with ischemic stroke or TIA with incidentally found cerebral microhemorrhages. An analysis of pooled data from multiple cohorts totaling 20,322 participants showed that recurrent symptomatic ischemic stroke ...

How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?

1
1 Answers

Mednet MemberInvited Expert
Radiation Oncology

My default recommendation for patients with localized, high-risk prostate cancer is to recommend the use of long-term ADT. This intervention seems to offer a relatively large, clinically significant OS benefit for patients in the modern era receiving dose-escalated ADT. This benefit has been observe...

How do you manage infection risk when using BTKi-chemoimmunotherapy combinations in MCL patients?

2 Answers

Mednet Member
Hematology · Fred Hutch Cancer Center

This is a broad question, but BTKi are used in younger/fit patients (TRIANGLE-like therapy, including cytarabine) and approved in combination with BR (acalabrutinib). Regarding the latter: bendamustine is known to be T-cell depleting and associated with zoster/HSV and risk of other viral infections....